LDE225B

Small molecule

LDE225B is one of 5 small molecule programs targeting Nevoid Basal Cell Carcinoma Syndrome. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nevoid Basal Cell Carcinoma SyndromeActive, not recruiting

Nevoid Basal Cell Carcinoma SyndromePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Nevoid Basal Cell Carcinoma Syndrome

#DrugCompanyPhaseTrials

Erivedge

Roche

Approved

—2

Visudyne

BBausch Health Americas, Inc.

Approved

—3

Levulan

BBiomed Industries, Inc.

LDE225

1 5

LDE225B

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nevoid Basal Cell Carcinoma Syndrome1 trial

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Withdrawn· Novartis logo

Novartis·Phase 2/3·NCT03070691

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LDE225B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LDE225B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LDE225B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Novartis

LDE225B

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nevoid Basal Cell Carcinoma Syndrome1 trial

References

Drug Info

Quick Facts

Related News